Research graph
References from Intravitreal faricimab in patients with <scp>nAMD</scp> : French data from the Fight Retinal Blindness! Registry. Local targets link to admitted publications; unresolved targets remain external evidence.
Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review
10.1186/s40942-021-00307-7 · 2021 · External reference
Severe intraocular inflammation after intravitreal injection of faricimab: a single‐site case series of six patients
10.1016/j.ajo.2024.08.008 · 2025 · External reference
European unmet needs in the management of neovascular age‐related macular degeneration in daily practice
10.1016/j.oret.2024.01.004 · 2024 · External reference
Short‐term efficacy of faricimab switch on retinal exudative signs in patients requiring frequent anti‐VEGF injections: a real‐life study
10.1177/11206721251374263 · 2025 · External reference
Predominantly persistent Intraretinal fluid in the comparison of age‐related macular degeneration treatments trials (CATT)
10.1016/j.oret.2022.03.024 · 2022 · External reference
Sterile intraocular inflammation associated with Faricimab
10.1001/jamaophthalmol.2024.3828 · 2024 · External reference
Ten‐year treatment outcomes of Neovascular age‐related macular degeneration from two regions
10.1016/j.ajo.2019.10.007 · 2020 · External reference
Efficient capture of high‐quality data on outcomes of treatment for macular diseases: the fight retinal blindness! Project
10.1097/iae.0b013e318296b271 · 2014 · External reference
One‐year outcomes after switching to Faricimab in eyes with pretreated Neovascular age‐related macular degeneration: a Swiss retina research network report
10.1016/j.oret.2025.03.015 · 2025 · External reference
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age‐related macular degeneration (TENAYA and LUCERNE): two randomised, double‐masked, phase 3, non‐inferiority trials
10.1016/s0140-6736(22)00010-1 · 2022 · External reference
Multi‐country real‐life experience of anti‐vascular endothelial growth factor therapy for wet age‐related macular degeneration
10.1136/bjophthalmol-2014-305327 · 2015 · External reference
Outcomes after switching to Faricimab in Neovascular age‐related macular degeneration: data from the fight retinal blindness! Registry
10.1111/ceo.14589 · 2025 · External reference
1‐year real‐world outcomes of faricimab in previously treated neovascular age‐related macular degeneration
10.1038/s41433-025-03616-5 · 2025 · External reference
Six‐month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age‐related macular degeneration
10.1007/s00417-023-06222-x · 2024 · External reference
TENAYA and LUCERNE: two‐year results from the phase 3 neovascular age‐related macular degeneration trials of faricimab with treat‐and‐extend dosing in year 2
10.1016/j.ophtha.2024.02.014 · 2024 · External reference
Functional and anatomical outcomes of Faricimab in previously treated wet age‐related macular degeneration: systematic review and pooled analysis
10.1007/s40123-025-01181-4 · 2025 · External reference
Short‐term outcomes of Faricimab treatment in Aflibercept‐refractory eyes with Neovascular age‐related macular degeneration
10.3390/jcm12155145 · 2023 · External reference
The role of retinal fluid location in atrophy and fibrosis evolution of patients with neovascular age‐related macular degeneration long‐term treated in real world
2021 · External reference
Factors associated with success of switching to faricimab for neovascular age‐related macular degeneration refractory to Intravitreal Aflibercept
10.3390/life14040476 · 2024 · External reference
Correlation of retinal fluid and photoreceptor and RPE loss in neovascular AMD by automated quantification, a real‐world FRB! Analysis
10.1111/aos.16799 · 2024 · External reference
One‐year clinical outcomes of four‐dose induction versus immediate treat‐and‐extend faricimab regimens in pretreated neovascular age‐related macular degeneration
10.1186/s12886-025-04463-4 · 2025 · External reference
Rates of ocular adverse events after Intravitreal Faricimab injections
10.1016/j.oret.2023.12.001 · 2024 · External reference
Intraocular inflammation associated with faricimab therapy: one‐year real‐world outcomes
10.1097/iae.0000000000004394 · 2025 · External reference
Predictive factors for injection interval extension after switching to faricimab in neovascular AMD: the FAR WEST multicentre study
10.1111/aos.70134 · 2026 · External reference
Long‐term effect of fluid volumes during the maintenance phase in neovascular age‐related macular degeneration in the real world: results from fight retinal blindness!
10.1016/j.jcjo.2023.10.017 · 2023 · External reference
Intravitreal Aflibercept injection for neovascular age‐related macular degeneration
10.1016/j.ophtha.2013.08.011 · 2014 · External reference
Short‐term outcomes of faricimab in patients with neovascular age‐related macular degeneration on prior anti‐VEGF therapy
10.1016/j.oret.2023.08.018 · 2024 · External reference
Therapeutic effects of faricimab on aflibercept‐refractory age‐related macular degeneration
10.1038/s41598-023-48190-6 · 2023 · External reference
